Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Innate Pharma SA ( (FR:IPH) ).
On May 27, 2025, Innate Pharma announced its participation in upcoming healthcare conferences, including the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. The company’s executive team will engage in fireside chats and meetings, highlighting Innate Pharma’s strategic efforts to enhance visibility and foster collaborations within the healthcare industry.
The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes innovative approaches to harness the innate immune system through its proprietary ANKET® platform for multi-specific NK Cell Engagers, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca to accelerate research and development.
Average Trading Volume: 119,439
Technical Sentiment Signal: Sell
Current Market Cap: €180.8M
Learn more about IPH stock on TipRanks’ Stock Analysis page.